Skip to main content

Advertisement

Table 1 Patients’ and treatment characteristics (n = 20)

From: Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

Category Distribution and%
Age (median, range) 61 (34–77)
2009 FIGO stage  
  IIIA 7 (35%)
  IIIC 5 (25%)
   IIIC1 2 (10%)
   IIIC2 3 (15%)
  IVB 7 (35%)
  No classification available * 1 (5%)
Histology  
  Endometrioid (pure) 13 (65%)
  Papillary serous (pure) 4 (20%)
  Papillary serous (mixed) 3 (15%)
Grade  
  1 3 (15%)
  2 7 (35%)
  3 10 (50%)
Nodal status  
  pN0 11 (55%)
  pN+ 6 (30%)
  pNx 3 (15%)
Peritoneal cytology  
  Positive or suspicious for malignant cells 15 (75%)
  Negative 4 (20%)
  Not done 1 (5%)
SURGERY  
  Surgical approach  
   Laparotomy 15 (75%)
   Laparoscopy 5 (25%)
  Lymph node dissection performed 17 (85%)
   Pelvic only 8 (40%)
   Pelvic + PA 9 (45%)
  Total number of dissected LN (median, range) 18 (3–46)
CHEMOTHERAPY  
  Number of cycles (received/planned)  
   0/6 cycles 2 (10%)
   3/3 cycles 2 (10%)
   4/6 cycles 1 (5%)
   5/6 cycles 1 (5%)
   6/6 cycles 14 (70%)
  Drug combination (n = 18)  
   TP 14 (78%)
   TAP 4 (22%)
RADIOTHERAPY  
  WAI total dose (median, range)  
   Total dose (Gy) 27.5 (20–30)
   Daily dose (Gy) 1.25 (1.0 - 1.25
  Additional volume (boost)  
   Pelvic only 7 (35%)
   Pelvic + PA 2 (10%)
  Cumulative total dose(median, range)  
   Pelvis (Gy) 46.7 (44.8 - 48)
   PA (Gy) 46.7 (44.8 - 55.7)
  Vaginal cuff brachytherapy 17 (85%)
  Dose (median, range)  
  Total dose (Gy) 18 (13–21)
  Number of fractions 3 (3–5)
TIMING (median, range)  
  Between surgery and chemo start (days) 24 (9–48)
  Between end of chemo and RT start (days) 48 (21–104)
  Between surgery and completion of all treatments (months) 5.7 (1.5 - 7.6)
  Duration of RT (elapsed days) 35 (11–55)
  1. *multifocal cancer arising from endometriosis.
  2. Abbreviations: Chemo Chemotherapy, LN Lymph nodes, PA Para-aortic, RT Radiotherapy, TP Paclitaxel (175 mg/m2) and Carboplatin (Area under the Curve [AUC] 5); TAP = Paclitaxel (175 mg/m2), Doxorubicin (45 mg/m2) and Carboplatin (AUC5).